Background and ObjectivesHonduras became the first lower middle‐income country (LMIC) to adopt amotosalen/UVA pathogen‐reduced (PR) platelet concentrates (PCs) as a national platelet safety measure in 2018. The Honduran Red Cross (HRC) produces ~70% of the national platelet supply using the platelet‐rich plasma (PRP) method. Between 2015 and 2018, PCs were screened with bacterial culture and issued as individual, non‐pooled PRP units with weight‐based dosing and 5‐day shelf‐life. PR PCs were produced in six‐PRP pools with a standardized dose (≥3.0 × 1011), no bacterial screening and 7‐day shelf‐life. Gamma irradiation and leukoreduction were not used.Materials and MethodsPC production and distribution data were retrospectively analysed in two periods. Period 1 (P1) included 3 years of PRP PCs and a transition year (2015–18). Period 2 (P2) included 5 years of PR PCs (2019–23). PC doses were standardized to an equivalent adult dose for both periods. Descriptive statistics were calculated.ResultsHRC produced 10% more PC doses per year on average in P2 compared to P1. Mean annual waste at HRC declined from 23.9% in P1 to 1.1% in P2. Two urban regions consumed 96% of PC doses in P1 and 88.3% in P2. PC distributions increased in 14/18 regions.ConclusionStandardized dosage, PR and 7‐day shelf‐life increased PC availability, reduced waste, eliminated bacterial screening and avoided additional costs for arboviral testing, leukoreduction and irradiation. Access to PC transfusion remains limited in Honduras; however, the conversion to pooled PR PCs illustrates the potential to sustainably expand PC distribution in an LMIC.